ADC Therapeutics SA (ADCT)

USD 1.91

(-10.33%)

Gross Profit Summary of ADC Therapeutics SA

ADC Therapeutics SA's latest annual gross profit in 2023 was 67.02 Million USD , down -67.36% from previous year.
ADC Therapeutics SA's latest quarterly gross profit in 2024 Q2 was 15.35 Million USD , up 4.46% from previous quarter.
ADC Therapeutics SA reported a annual gross profit of 205.32 Million USD in annual gross profit 2022, up 531.32% from previous year.
ADC Therapeutics SA reported a annual gross profit of 32.52 Million USD in annual gross profit 2021, up 1749.29% from previous year.
ADC Therapeutics SA reported a quarterly gross profit of 15.35 Million USD for 2024 Q2, up 4.46% from previous quarter.
ADC Therapeutics SA reported a quarterly gross profit of 17.96 Million USD for 2023 Q2, down -2.38% from previous quarter.

Annual Gross Profit Chart of ADC Therapeutics SA (2023 - 2017)

Historical Annual Gross Profit of ADC Therapeutics SA (2023 - 2017)

Year	Gross Profit	Gross Profit Growth
2023	67.02 Million USD	-67.36%
2022	205.32 Million USD	531.32%
2021	32.52 Million USD	1749.29%
2020	-1.97 Million USD	98.13%
2019	-105.19 Million USD	10.05%
2018	-116.94 Million USD	-39.68%
2017	-83.72 Million USD	0.0%

Year	Gross Profit	Gross Profit Growth
2024 Q1	14.7 Million USD	-5.62%
2024 Q2	15.35 Million USD	4.46%
2023 Q2	17.96 Million USD	-2.38%
2023 Q3	14.12 Million USD	-21.36%
2023 Q1	18.4 Million USD	-73.45%
2023 FY	67.02 Million USD	-67.36%
2023 Q4	15.57 Million USD	10.25%
2022 Q4	69.3 Million USD	-7.62%
2022 Q3	75.02 Million USD	399.34%
2022 Q2	15.02 Million USD	-67.31%
2022 FY	205.32 Million USD	531.32%
2022 Q1	45.96 Million USD	183.06%
2021 FY	32.52 Million USD	1749.29%
2021 Q3	12.64 Million USD	247.49%
2021 Q1	-578 Thousand USD	-102.23%
2021 Q4	16.24 Million USD	28.43%
2021 Q2	3.63 Million USD	729.58%
2020 Q1	-35.37 Million USD	-16.27%
2020 FY	-1.97 Million USD	98.13%
2020 Q2	-25.95 Million USD	26.64%
2020 Q3	-32.15 Million USD	-23.91%
2020 Q4	25.95 Million USD	180.7%
2019 Q4	-30.42 Million USD	0.38%
2019 Q3	-30.54 Million USD	-54.26%
2019 Q2	-19.79 Million USD	10.48%
2019 Q1	-22.11 Million USD	23.29%
2019 FY	-105.19 Million USD	10.05%
2018 Q3	-28.83 Million USD	2.73%
2018 Q2	-29.64 Million USD	0.0%
2018 FY	-116.94 Million USD	-39.68%
2018 Q1	-29.64 Million USD	0.0%
2018 Q4	-28.83 Million USD	0.0%
2017 FY	-83.72 Million USD	0.0%

Peer Gross Profit Comparison of ADC Therapeutics SA

Name	Gross Profit	Gross Profit Difference
Alto Neuroscience, Inc.	-373 Thousand USD	18070.241%
Annovis Bio, Inc.	- USD	-Infinity%
Biohaven Pharmaceutical Holding Company Ltd.	-3.36 Million USD	2089.581%
Ginkgo Bioworks Holdings, Inc.	197.45 Million USD	66.053%
Nuvation Bio Inc.	-222 Thousand USD	30293.243%
Nuvation Bio Inc.	-222 Thousand USD	30293.243%
Arcus Biosciences, Inc.	-223 Million USD	130.058%
Theriva Biologics, Inc.	-135 Thousand USD	49751.111%
Zymeworks Inc.	-66.97 Million USD	200.078%